$CURLF

Aurora Cannabis (ACB) urged shareholders to reject Curaleaf's (CURA) hostile takeover bid, citing its debt-free status and $149M cash position. Aurora's CEO criticized the offer, claiming it undervalues assets and shifts risks. Curaleaf's CEO expressed willingness to discuss the merger, which was proposed at $4 per Aurora share.

Curaleaf (TSX:CURA) shares fell 4.77% on September 3, 2026, despite a broader market rally. The decline was attributed to uncertainty around its acquisition proposal for Aurora Cannabis, which was rejected. Investors are reassessing risks related to leverage, regulation, and cannabis sector volatility. Curaleaf operates a diversified cannabis business with domestic and international operations, but faces challenges in execution and balance-sheet management.

Curaleaf (CURLF) issued a press release on September 2, 2026, responding to Aurora Cannabis. The release is furnished under Form 8-K Item 8.01 and is not deemed filed for Exchange Act purposes. It is included as Exhibit 99.1, with Peter Clateman, Chief Legal Officer, signing the filing.

Curaleaf (CURA, CURLF) defended its acquisition offer for Aurora Cannabis (ACB), citing a 45% premium and superior financials. Aurora's management has diluted shareholders through equity issuances and faces declining revenue and EBITDA, according to Curaleaf. Aurora's board sold shares below the offer price, contradicting its valuation argument.

Curaleaf Holdings defended its takeover bid for Aurora Cannabis, arguing its offer provides a 45% premium and long-term benefits. Aurora's board unanimously recommended shareholders reject the bid, citing undervaluation and risks. Curaleaf criticized Aurora's financial outlook and equity dilution, while Aurora maintained the offer undervalues the company. Curaleaf reported positive cash flow and growth investments for 2026.

Aurora Cannabis (ACB) is advising shareholders to reject Curaleaf's hostile takeover offer, calling it undervalued. Aurora highlights its debt-free status and C$149M cash, contrasting with Curaleaf's C$1B debt. Curaleaf's offer is US$4.00 per Aurora share, including shares and cash. Aurora shares closed at C$5.60 on the TSX.

Aurora Cannabis (ACB) disputed inaccuracies in Curaleaf's (CURLF) takeover bid, stating its financial performance is stronger than portrayed. Aurora's board is reviewing the proposal. Curaleaf offered $4.00 per Aurora share, including shares and cash. Aurora's CEO claims the bid undervalues the company and its EU-GMP infrastructure. ACB shares are down 9% YTD, while CURLF shares are up 27%.

Curaleaf's $4 per share hostile bid for Aurora Cannabis led to public disputes. Aurora urged shareholders to wait, calling Curaleaf's claims inaccurate. Curaleaf emphasized its premium offer. Aurora highlighted its EU-GMP facilities and recent acquisitions, while Curaleaf's shares rose 8% in the past year, Aurora's fell 23%.

An informal poll by The Marijuana Herald found 90% of Aurora Cannabis investors oppose Curaleaf's takeover bid, while 64% of Curaleaf investors support it. Aurora investors cite undervaluation, Curaleaf highlights strategic benefits. Curaleaf's offer is $4 per Aurora share, a 45% premium according to the company. Aurora's board is reviewing the offer.

Curaleaf claims Aurora's cultivation yield is 114 grams per plant, per Aurora's audited 2026 statements, and asserts its own yields are more than double. Curaleaf criticizes Aurora's financial performance, citing revenue declines and negative cash flow. Aurora disputes Curaleaf's claims. Curaleaf's offer is based on Aurora's August 5 numbers, with no recommendation from Aurora's Special Committee.